eukaryotic translation initiation factor 4E binding protein 2Genealiases: 4EBP2 · PHASII
Q-omics provides the consensus-scored EIF4EBP2 profile across patient tissues and cancer cell-line models. EIF4EBP2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EIF4EBP2 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, EIF4EBP2 RNA expression shows 20,176 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where EIF4EBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF4EBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF4EBP2 survival associations across molecular data types. EIF4EBP2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF4EBP2 RNA expression–survival associations across cancer types. High EIF4EBP2 expression shows unfavorable associations in ACC, but favorable associations in KIRC, MESO, LGG, UCS and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EIF4EBP2 RNA expression.
This table summarizes EIF4EBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EIF4EBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF4EBP2 shows lower tumor expression in BLCA, COAD, BRCA, LUAD and KIRP and higher tumor expression in LIHC. The BLCA box plot shows higher EIF4EBP2 RNA expression in normal versus tumor tissue (log2 FC = −0.852, t-test p < 0.001).
This table shows molecular features associated with EIF4EBP2 in patient tissues and cancer cell lines. In patient samples, EIF4EBP2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EIF4EBP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
